-
Je něco špatně v tomto záznamu ?
Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring Pt II chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand
J. Kasparkova, T. Suchankova, A. Halamikova, L. Zerzankova, O. Vrana, N. Margiotta, G. Natile, V. Brabec
Jazyk angličtina Země Velká Británie
Typ dokumentu práce podpořená grantem, srovnávací studie
- MeSH
- buněčná membrána metabolismus účinky léků MeSH
- cyklohexylaminy farmakologie chemie metabolismus MeSH
- DNA nádorová metabolismus MeSH
- glutathion metabolismus MeSH
- HeLa buňky MeSH
- králíci MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- nosiče léků chemie metabolismus toxicita MeSH
- oprava DNA fyziologie účinky léků MeSH
- organoplatinové sloučeniny metabolismus toxicita MeSH
- protinádorové látky farmakologie chemie metabolismus MeSH
- skot MeSH
- sloučeniny platiny chemie metabolismus toxicita MeSH
- zvířata MeSH
- Check Tag
- králíci MeSH
- lidé MeSH
- skot MeSH
- zvířata MeSH
- Publikační typ
- práce podpořená grantem MeSH
- srovnávací studie MeSH
Earlier studies have described promising antitumor activity of a large-ring chelate complex [PtCl(2)(cis-1,4-DACH)] (DACH=diaminocyclohexane). Encouraging antitumor activity of this analogue of cisplatin prompted us to perform studies focused on the mechanistic basis of pharmacological effects of this complex. Four early steps in the mechanism of biological activity of cisplatin have been delineated: cell entry, reactions with sulfur-containing compounds, platinum-DNA binding along with processing platinated DNA by proteins (enzymes) and DNA repair. Here, we describe comparative experiments (involving also cisplatin) revealing: (i) improved cytotoxicity (3.4-5.4-fold) of [PtCl(2)(cis-1,4-DACH)] in human tumor ovarian cell lines; (ii) enhanced cellular uptake (approximately 1.5-fold) of [PtCl(2)(cis-1,4-DACH)]; (iii) somewhat enhanced rate of reactions of [PtCl(2)(cis-1,4-DACH)] with glutathione (approximately 1.5-fold), but a similar rate of reactions with metallothionenin-2; (iv) enhanced rate of DNA binding of [PtCl(2)(cis-1,4-DACH)] in cell-free media (approximately 2-fold); (v) similar sequence preference of DNA binding of [PtCl(2)(cis-1,4-DACH)] in cell-free media; (vi) identical DNA interstrand cross-linking efficiency (6%); (vii) similar bending (32 degrees) and enhanced local unwinding (approximately 1.5-fold) induced in DNA by the major 1,2-GG-intrastrand cross-link; (viii) markedly enhanced inhibiting effects of DNA adducts of [PtCl(2)(cis-1,4-DACH)] on processivity of DNA polymerase; and (ix) a slightly lower efficiency of DNA repair systems to remove the adducts of [PtCl(2)(cis-1,4-DACH)] from DNA.
- 000
- 04109naa a2200625 a 4500
- 001
- bmc12008460
- 003
- CZ-PrNML
- 005
- 20130324221233.0
- 008
- 120316s2010 xxk eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $d ABA008
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kašpárková, Jana, $d 1969- $7 xx0068609 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Kralovopolska 135, CZ-61265 Brno, Czech Republic
- 245 10
- $a Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring Pt II chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand./ $c J. Kasparkova, T. Suchankova, A. Halamikova, L. Zerzankova, O. Vrana, N. Margiotta, G. Natile, V. Brabec
- 520 9_
- $a Earlier studies have described promising antitumor activity of a large-ring chelate complex [PtCl(2)(cis-1,4-DACH)] (DACH=diaminocyclohexane). Encouraging antitumor activity of this analogue of cisplatin prompted us to perform studies focused on the mechanistic basis of pharmacological effects of this complex. Four early steps in the mechanism of biological activity of cisplatin have been delineated: cell entry, reactions with sulfur-containing compounds, platinum-DNA binding along with processing platinated DNA by proteins (enzymes) and DNA repair. Here, we describe comparative experiments (involving also cisplatin) revealing: (i) improved cytotoxicity (3.4-5.4-fold) of [PtCl(2)(cis-1,4-DACH)] in human tumor ovarian cell lines; (ii) enhanced cellular uptake (approximately 1.5-fold) of [PtCl(2)(cis-1,4-DACH)]; (iii) somewhat enhanced rate of reactions of [PtCl(2)(cis-1,4-DACH)] with glutathione (approximately 1.5-fold), but a similar rate of reactions with metallothionenin-2; (iv) enhanced rate of DNA binding of [PtCl(2)(cis-1,4-DACH)] in cell-free media (approximately 2-fold); (v) similar sequence preference of DNA binding of [PtCl(2)(cis-1,4-DACH)] in cell-free media; (vi) identical DNA interstrand cross-linking efficiency (6%); (vii) similar bending (32 degrees) and enhanced local unwinding (approximately 1.5-fold) induced in DNA by the major 1,2-GG-intrastrand cross-link; (viii) markedly enhanced inhibiting effects of DNA adducts of [PtCl(2)(cis-1,4-DACH)] on processivity of DNA polymerase; and (ix) a slightly lower efficiency of DNA repair systems to remove the adducts of [PtCl(2)(cis-1,4-DACH)] from DNA.
- 536 __
- $c Grant Number: (United States Howard Hughes Medical Institute)
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a zvířata $7 D000818
- 650 02
- $a protinádorové látky $x farmakologie $x chemie $x metabolismus $7 D000970
- 650 02
- $a skot $7 D002417
- 650 02
- $a nádorové buněčné linie $7 D045744
- 650 02
- $a buněčná membrána $x metabolismus $x účinky léků $7 D002462
- 650 02
- $a cyklohexylaminy $x farmakologie $x chemie $x metabolismus $7 D003514
- 650 02
- $a oprava DNA $x fyziologie $x účinky léků $7 D004260
- 650 02
- $a DNA nádorová $x metabolismus $7 D004273
- 650 02
- $a nosiče léků $x chemie $x metabolismus $x toxicita $7 D004337
- 650 02
- $a glutathion $x metabolismus $7 D005978
- 650 02
- $a HeLa buňky $7 D006367
- 650 02
- $a lidé $7 D006801
- 650 02
- $a organoplatinové sloučeniny $x metabolismus $x toxicita $7 D009944
- 650 02
- $a sloučeniny platiny $x chemie $x metabolismus $x toxicita $7 D017671
- 650 02
- $a králíci $7 D011817
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Suchánková, Tereza, $d 1983- $7 mub2011617906
- 700 1_
- $a Halámiková, Anna. $7 mub2011652620
- 700 1_
- $a Marková, Lenka. $7 xx0308463
- 700 1_
- $a Vrána, Oldřich, $d 1956- $7 xx0097595
- 700 1_
- $a Margiotta, Nicola
- 700 1_
- $a Natile, Giovanni
- 700 1_
- $a Brabec, Viktor, $d 1944- $7 jo20010087133
- 773 0_
- $t Biochemical Pharmacology $p Biochem Pharmacol $g Roč. 79, č. 4 (2010), s. 552-564 $w MED00000704 $x 0006-2952
- 910 __
- $a ABA008 $b x $y 4
- 990 __
- $a 20120319124427 $b ABA008
- 991 __
- $a 20130324221503 $b ABA008
- 999 __
- $a ok $b bmc $g 901855 $s 765355
- BAS __
- $a 3
- BMC __
- $a 2010 $b 79 $c 4 $d 552-564 $m Biochemical pharmacology $x MED00000704 $i 0006-2952 $n Biochem Pharmacol
- LZP __
- $a 2012-1Q10/jt